Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest’s Sigh Of Relief: Aerospan Is Approved

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest receives approval on Jan. 27 for a non-CFC formulation of its asthma therapy Aerobid.

You may also be interested in...

CFC-Containing Albuterol Inhalers To Be Removed By 2009

FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.

Forest Not Holding Its Breath For Aerospan

Forest does not expect a near-term approval for Aerospan (flunisolide), a non-CFC formulation of its asthma therapy Aerobid

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts